Early research showed that a high degree of CD8+ and CD4+ T-cell infiltration in ESCC correlated with favorable clinical outcome, suggesting that the tumor antigen-specific cellular immune response plays a role in the clinical disease course [16–18]. The gene discussed is CD4; the disease is esophageal squamous cell carcinoma.